BN Business News
Add your company to Business Communicator →

Business · 18/11/20261 min read

New three-year real-world data on Leqembi® presented at CTAD 2026

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

STOCKHOLM, November 18, 2026 — BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) study[1]. The data showed that patients treated with Leqembi had a 76% lower rate of...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →